# A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors

> **NCT06508307** · PHASE1 · RECRUITING · sponsor: **GONGCHU Biotechnology Co., Ltd** · enrollment: 21 (estimated)

## Conditions studied

- Sarcoma
- Cervical Cancer
- Colon Cancer
- Lung Cancer
- Ovarian Cancer
- Pancreatic Cancer
- Hepatocellular Carcinoma
- Breast Cancer
- Gastric Cancer

## Interventions

- **BIOLOGICAL:** A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patients With Advanced Solid Tumors

## Key facts

- **NCT ID:** NCT06508307
- **Lead sponsor:** GONGCHU Biotechnology Co., Ltd
- **Sponsor class:** OTHER
- **Phase:** PHASE1
- **Study type:** INTERVENTIONAL
- **Status:** RECRUITING
- **Start date:** 2023-04-26
- **Primary completion:** 2026-01
- **Final completion:** 2026-06
- **Target enrollment:** 21 (ESTIMATED)
- **Last updated:** 2025-08-21


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT06508307

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT06508307, "A Phase I Clinical Study of Intratumoral Injection Oncolytic Vaccinia Virus GC001 in Patient With Advanced Solid Tumors". Retrieved via AI Analytics 2026-05-26 from https://api.ai-analytics.org/clinical/NCT06508307. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*